Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-to-treat population. RESULTS: At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001). Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, respectively. Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. CONCLUSIONS: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906 ; Eudra-CT number, 2014-002351-26 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [191]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Research works printed but not linked: 1
- Tarhini AA, 2017, J Clin Oncol, 35
Cited by
Items 901–1,000 of 1,000
Recent advances in the management of cutaneous malignant melanoma: our case cohort
Sayan, A., Plant, R. E., Eccles, B., Davies, C., & Ilankovan, V. (2020) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2020.11.008 · Cited by 16
Khunger, A., Sarikonda, G., Tsau, J., Pahuja, A., Alfonso, Z., Gao, J., Laing, C., Vaupel, C., Dakappagari, N. K., & Tarhini, A. A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101014 · Cited by 17
Livingstone, A., Milne, D., Dempsey, K., Muscat, D. M., Menzies, A. M., Howard, K., Stockler, M. R., & Morton, R. L. (2021) · Patient · doi:10.1007/s40271-021-00507-1 · Cited by 15
Koelblinger, P., Hoellwerth, M., Dernoscheg, M., Koch, L., Richtig, E., Wanner, M., Nguyen, V., Ostermann, H., Bauer, J. W., & Laimer, M. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14511 · Cited by 15
Rossi, E., Schinzari, G., Maiorano, B. A., Esposito, I., Acampora, A., Romagnoli, J., Stefani, A. D., Regno, L. D., Lancellotta, V., Fionda, B., et al. (2021) · Immunotherapy · doi:10.2217/imt-2021-0195 · Cited by 17
Andersen, J. A. S., Spatzek, A. D., Vilstrup, M. H., Grupe, P., Hess, S., Holdgaard, P. C., Bastholt, L., Gerke, O., & Hildebrandt, M. G. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05704-0 · Cited by 18
“While the use of FDG-PET/CT in diagnosing MM recurrence and the value of nivolumab in adjuvant treatment has been described [5, 8], the diagnostic accuracy and optimal frequency of FDG-PET/CT in patients treated with adjuvant nivolumab have, to the best of our knowledge, not yet been examined [3, 14].”
BackgroundMethodDieng, M., Lord, S. J., Turner, R. M., Nieweg, O. E., Menzies, A. M., Saw, R. P. M., Einstein, A. J., Emmett, L., Thompson, J. F., Lo, S., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11231-3 · Cited by 15
“Thus, the role of imaging is increasingly relevant and several randomized trial protocols of adjuvant treatment for patients with resected stage III melanoma have required imaging every 12 weeks.(11,12) Without randomized trials to estimate any survival benefit of earlier versus later detection and treatment of distan…”
BackgroundMonoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
Graziani, G., Lisi, L., Tentori, L., & Navarra, P. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_10 · Cited by 21
Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma
Holmstroem, R. B., Pedersen, S., Jurlander, R. S., Madsen, K. S., Donia, M., Ruhlmann, C. H. B., Schmidt, H., Haslund, C. A., Bastholt, L., Svane, I. M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114023 · Cited by 17
Surgical damage to the lymphatic system promotes tumor growth via impaired adaptive immune response
Nakamura, Y., Fujisawa, Y., Okiyama, N., Watanabe, R., Tanaka, R., Ishitsuka, Y., Tahara, H., & Fujimoto, M. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.12.016 · Cited by 15
Lim, K. H. J., Spain, L. A., Barker, C., Georgiou, A., Walls, G., Gore, M. E., Turajlic, S., Ruth Board, Larkin, J., & Lorigan, P. C. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000317 · Cited by 16
“Ipilimumab has been shown to improve overall survival compared with placebo(20); however, nivolumab has recently demonstrated improved recurrence-free survival compared with ipilimumab.(21) The combination of dabrafenib and trametinib also improves recurrence-free survival over placebo.”
BackgroundSelf-citationKwon, M., Choi, Y. J., Sa, M., Park, S., & Shin, E. (2018) · Immune Network · doi:10.4110/in.2018.18.e45 · Cited by 16
“As of 2018, 2 anti-PD-1 Abs (nivolumab and pembrolizumab) and 3 anti-PD-L1 Abs (atezolizumab, avelumab, and durvalumab) have been approved by the US Food and Drug Administration for the treatment of various cancers, including malignant melanoma (2,3), non-small cell lung cancer (4-6), head and neck squamous cell cance…”
BackgroundImpact of Immunotherapy after Resection of Pancreatic Cancer
Tran, T. B., Maker, V. K., & Maker, A. V. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2019.01.016 · Cited by 16
“Specifically, FDA-approval has already been granted for the use of either adjuvant nivolumab or pembrolizumab in advanced melanoma(29, 30), cervical cancer(31), bladder cancer(19, 32), and renal cancer(33) based on the results of recent clinical trials.”
BackgroundProlonged overall survival following metastasectomy in stage IV melanoma
Elias, M. L., Behbahani, S., Maddukuri, S., John, A. M., Schwartz, R. A., & Lambert, W. C. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15667 · Cited by 17
Long, G. V., Tang, H. T., Desai, K., Wang, S., Vecchio, M. D., Larkin, J., Ritchings, C., Huang, S., Baden, J. F., Balli, D., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012034 · Cited by 21
Self-citationJochems, A., Bastiaannet, E., Aarts, M. J. B., van Akkooi, A. C. J., van den Berkmortel, F. W. P. J., Boers‐Sonderen, M. J., van den Eertwegh, A. J. M., de Glas, N. A., de Groot, J. W. B., Haanen, J. B. A. G., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.04.006 · Cited by 14
PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
Cristinziano, L., Modestino, L., Capone, M., Madonna, G., Mallardo, D., Giannarelli, D., D’Angelo, G., Ferrara, A. L., Loffredo, S., Varricchi, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962669 · Cited by 16
“Finally, since stage III melanoma patients are currently considered candidates for anti-PD-1 therapy (4, 57), it would be necessary to assess whether PD-L1 PMNs predict clinical outcomes in patients other than stage IV melanoma.”
BackgroundSelf-citationEgeler, M., van Leeuwen, M., Fraterman, I., Heuvel, N. M. J. V. D., Boekhout, A. H., Lai-Kwon, J. E., Wilthagen, E. A., Eriksson, H., Haanen, J. B. A. G., Wilgenhof, S., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103919 · Cited by 15
Self-citationMelanoma—the therapeutic considerations in the clinical practice
Adeleke, S. M., Okoli, S., Augustine, A., Galante, J. R., Agnihotri, A., Uccello, M., Ghose, A., Moschetta, M., & Boussios, S. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-1432 · Cited by 14
Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond
Patel, M., Hudson, O., Han, J., Kondapalli, L., Arora, G., Hawi, R., Andrikopoulou, E., Estes, C., Johnson, A. M., & Lenneman, C. G. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01130-y · Cited by 15
Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence
Vaidya, P., & Cohen, E. E. W. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0583 · Cited by 16
Adjuvant treatment with anti‐ PD ‐1 in acral melanoma: A nationwide study
Bloem, M., van Not, O. J., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Blokx, W. A. M., Boers‐Sonderen, M. J., Bonenkamp, H. J., de Groot, J. B., Haanen, J. B. A. G., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35060 · Cited by 18
Özkan, A., Kapiteijn, E., van den Bos, F., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C., Bloem, M., Blokx, W. A. M., Boers‐Sonderen, M. J., Bonenkamp, J. J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115056 · Cited by 15
“In our population, grade ≥ 3 irAEs were observed in 15.0 % of the patients, which is consistent with findings from earlier adjuvant trials, such as the 14.4 % reported in the Checkmate-238 trial and the 14.7 % in the EORTC 1325/Keynote-054 trial [5,22].”
InfluentialBraf-Mutant Melanomas: Biology and Therapy
Pelosi, E., Castelli, G., & Testa, U. (2024) · Current Oncology · doi:10.3390/curroncol31120568 · Cited by 17
“The randomized phase III Check Mate 238 study compared the safety and the efficacy of nivolumab and ipilimumab in 906 melanoma patients with stage IIIB, IIIC, or IV tumors surgically resected [51].”
InfluentialSinnamon, A. J., Song, Y., Sharon, C. E., Yang, Y., Elder, D. E., Zhang, P. J., Xu, X., Roses, R. E., Kelz, R. R., Fraker, D. L., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6647-7 · Cited by 18
Farrow, N. E., Turner, M. C., Salama, A. K. S., & Beasley, G. M. (2020) · Oncology and Therapy · doi:10.1007/s40487-020-00117-1 · Cited by 14
Fonseca, I. B., Lindote, M. V. N., Monteiro, M. R., Filho, E. D., Pinto, C. A. L., Jafelicci, A. S., Lobo, M. D. M., Calsavara, V. F., Bertolli, E., & Neto, J. P. D. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08959-9 · Cited by 15
Xu, L., & Li, C. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210618100857 · Cited by 15
Smithers, B. M., Saw, R. P. M., Gyorki, D. E., Martin, R. C. W., Atkinson, V. G., Haydon, A. M., Roberts‐Thomson, R., & Thompson, J. F. (2021) · ANZ Journal of Surgery · doi:10.1111/ans.17051 · Cited by 17
Self-citationCheckpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease
Dietz, H., Weinmann, S. C., & Salama, A. K. S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s283217 · Cited by 18
Lanier, C. M., LeCompte, M. C., Glenn, C. W., Hughes, R. T., Isom, S. P., Jenkins, W., Cramer, C. K., Chan, M., Tatter, S. B., & Laxton, A. W. (2021) · Cureus · doi:10.7759/cureus.19967 · Cited by 14
“Stereotactic radiosurgery (SRS) has become the standard of treatment for oligometastatic brain metastases [2,3].”
BackgroundBroman, K. K., Richman, J., & Bhatia, S. (2022) · Surgery · doi:10.1016/j.surg.2021.12.025 · Cited by 15
Self-citationLodde, G. C., Zimmer, L., Livingstone, E., Schadendorf, D., & Ugurel, S. (2019) · Der Hautarzt · doi:10.1007/s00105-019-04514-0 · Cited by 35
Kiuru, M. H., Li, Q., Zhu, G., Terrell, J. R., Beroukhim, K., Maverakis, E., & Keegan, T. H. M. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18458 · Cited by 15
van Laar, S. A., Kapiteijn, E., Handoko, K. B., Guchelaar, H., & Zwaveling, J. (2022) · Cancers · doi:10.3390/cancers14215426 · Cited by 15
“Besides, manifestations of thyroiditis, hyperthyroidism (N: 15%, P: 13%) and hypothyroidism (N: 20%, P: 19%) seemed to occur more often in this study than in the trials (hyperthyroidism, N: 8%, P: 10%; hypothyroidism: N: 10%, 14%) [8,12].”
BackgroundResultInfluentialManzano, J. L., Martín-Liberal, J., Fernandez-Morales, L. A., Benítez, G., Martínez, J. M., Quindós, M., García‐Castaño, A., Fernández, O., Simó, R. V., Majem, M., et al. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000888 · Cited by 13
The Role of Nivolumab in Melanoma
Gomes, F., Serra-Bellver, P., & Lorigan, P. C. (2018) · Future Oncology · doi:10.2217/fon-2017-0484 · Cited by 20
Lattanzi, M. W., Han, J. K., Moran, U., Utter, K., Tchack, J., Sabado, R. L., Berman, R. S., Shapiro, R. L., Huang, H.-H., Osman, I., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0345-7 · Cited by 16
“[2] demonstrated significant efficacy of the anti- programmed death receptor 1 (antiPD-1) antibody, nivolumab, in preventing melanoma recurrence when administered following complete surgical resection.”
BackgroundThe effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies
Smith, H. G., Wilkinson, M., Smith, M. J. F., Strauß, D., & Hayes, A. J. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.04.014 · Cited by 14
Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor
Jiang, X., Li, L., Li, Y., & Li, Q. (2019) · Journal of Cancer · doi:10.7150/jca.26481 · Cited by 17
Song, Y., Tieniber, A. D., Gimotty, P. A., Mitchell, T. C., Amaravadi, R. K., Schuchter, L. M., Fraker, D. L., & Karakousis, G. C. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07599-y · Cited by 14
An Update on Adjuvant Systemic Therapies in Melanoma
Samuel, E., Moore, M. A., Voskoboynik, M., Shackleton, M. J., & Haydon, A. M. (2019) · Melanoma Management · doi:10.2217/mmt-2019-0009 · Cited by 16
Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer
Doumas, S., Foukas, P. G., Economopoulou, P., Kotsantis, I., & Psyrri, A. K. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104477 · Cited by 14
Zhang, P., Xiong, X., Rolfo, C. D., Du, X., Zhang, Y., Yang, H., Russo, A., Devenport, M., Zhou, P., Liu, Y., et al. (2020) · Cancers · doi:10.3390/cancers12020284 · Cited by 15
Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma
Lu, J. E., Chang, J. R., Berry, J. L., In, G. K., & Zhang-Nunes, S. (2020) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000308 · Cited by 14
Eggermont, A. M. M., Rutkowski, P. L., Dutriaux, C., Hofman‐Wellenhof, R., Dziewulski, P. G., Marples, M., Grange, F., Lok, C., Pennacchioli, E., Robert, C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.015 · Cited by 14
Self-citationAdverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes
Aktürk, H. K., & Michels, A. W. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000546 · Cited by 15
“elanoma The New England Journal of Medicine 2017 [17]”
BackgroundAdjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma
Bruce, W. J., Koljonen, J. L., Romanelli, M. R., Khan, A. U., & Neumeister, M. W. (2021) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2021.06.001 · Cited by 13
Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral, T. M. S., Meraz-Torres, F., & Garbe, C. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1378640 · Cited by 15
Klemen, N. D., Han, G., Leong, S. P. L., Kashani–Sabet, M., Vetto, J. T., White, R. L., Schneebaum, S., Pockaj, B. A., Mozzillo, N., Charney, K. J., et al. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25444 · Cited by 14
“Moreover, all of these questions are overshadowed by the recent advances in systemic therapy for melanoma, which have shown efficacy in the adjuvant setting for resected stage III patients by improving recurrence‐free survival but are also associated with a definite toxicity rate.(25)”
BackgroundGambichler, T., Schröter, U., Höxtermann, S., Susok, L., Stockfleth, E., & Becker, J. C. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000277 · Cited by 16
Gerbasi, M. E., Stellato, D., Ghate, S. R., Ndife, B. C., Moynahan, A., Mishra, D., Gunda, P., Koruth, R., & Delea, T. E. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1635487 · Cited by 16
Teras, J., Kroon, H. M., Miura, J. T., Kenyon-Smith, T., Beasley, G. M., Mullen, D., Farrow, N. E., Mosca, P. J., Lowe, M., Farley, C. R., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08312-0 · Cited by 14
Bischoff, J., Fries, C., Heer, A., Hoffmann, F., Meyer, C. H., Landsberg, J., & Fenske, W. K. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac036 · Cited by 15
“In metastatic melanoma, ICI-based immunotherapy radically modified cancer management by demonstrating long-lasting remissions in metastatic melanoma and a significant benefit in relapsefree survival in the adjuvant setting for patients with stage III or IV resected melanoma [10, 11].”
BackgroundWeber, J. S., Poretta, T., Stwalley, B. D., Sakkal, L. A., Du, E. X., Wang, T., Chen, Y., Wang, Y., Betts, K. A., & Shoushtari, A. N. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03302-5 · Cited by 13
“In the pivotal phase III CheckMate 238 trial, nivolumab was compared with ipilimumab for the adjuvant treatment of patients with stage III/IV melanoma who underwent complete resection, whereby it significantly improved RFS at 48 months and had a more favorable toxicity profile at 18 months [11, 12].”
MethodInfluentialSelf-citationZaremba, A., Mohr, P., Gutzmer, R., Meier, F. E., Pföhler, C., Weichenthal, M., Terheyden, P. A. M., Forschner, A., Leiter, U., Ulrich, J., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.008 · Cited by 13
Lucci, A., Addanki, S., Chiang, Y., Meas, S., Sarli, V. N., Upshaw, J. R., Manchem, M., Patel, S. P., Wargo, J. A., Gershenwald, J. E., et al. (2023) · Cancers · doi:10.3390/cancers15143630 · Cited by 13
Amaral, T. M. S., Nanz, L., Stadler, R., Berking, C., Ulmer, A., Forschner, A., Meiwes, A., Wolfsperger, F., Meraz-Torres, F., Chatziioannou, E., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113912 · Cited by 14
Radiation and Melanoma: Where Are We Now?
Bliley, R., Avant, A., Medina, T. M., & Lanning, R. M. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01557-y · Cited by 13
“Neoadjuvant/adjuvant IO or adjuvant BRAFi / MEKi are now considered standard of care [52 • , 53, 54 • , 55, 56].”
Distant lymph nodes compensate for resected tumor-draining lymph nodes during cancer immunotherapy
Menzel, L., Zhou, H., Baish, J. W., O’Melia, M. J., Darragh, L. B., Effiom, D. N., Specht, E., Czapla, J., Lei, P., Rajotte, J. J., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.09.009 · Cited by 14
Block, M. S., Nevala, W. K., Pang, Y., Allred, J. B., Strand, C. A., & Markovic, S. N. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000556 · Cited by 13
Song, Y., Shannon, A. B., Fraker, D. L., & Karakousis, G. C. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25600 · Cited by 13
Lorenzi, M. F., Arndorfer, S., Aguiar‐Ibáñez, R., Scherrer, E., Liu, F. X., & Krepler, C. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1649266 · Cited by 13
Sharma, R., Koruth, R., Kanters, S., Druyts, E., & Tarhini, A. A. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0061 · Cited by 13
Role of Surgery in Stage IV Melanoma
O’Neill, C. H., McMasters, K. M., & Egger, M. E. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.02.010 · Cited by 13
Pediatric Melanoma—Diagnosis, Management, and Anticipated Outcomes
Aldrink, J. H., Polites, S. F., & Austin, M. T. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.11.005 · Cited by 16
Percik, R., Asher, N., & Liel, Y. (2021) · Immunotherapy · doi:10.2217/imt-2020-0332 · Cited by 13
Ryan, A. L., Burns, C., Gupta, A., Samarasekera, R., Ziegler, D. S., Kirby, M. L., Alvaro, F., Downie, P., Laughton, S. J., Cross, S. F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.660172 · Cited by 13
“In addition, the highly immunogenic nature of melanoma has successfully been exploited using immunotherapy, with major improvements in patient outcomes (16).”
BackgroundChick, R. C., Faries, M. B., Hale, D. F., Bohan, P. M. K., Hickerson, A. T., Vreeland, T. J., Myers, J. W., Cindass, J. L., Brown, T. A., Hyngstrom, J. R., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3969 · Cited by 18
Emerging Therapies in the Treatment of Advanced Melanoma
Massand, S., & Neves, R. I. (2021) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2021.06.008 · Cited by 14
Skeletal muscle is prognostic in resected stage III malignant melanoma
Youn, S., Eurich, D. T., McCall, M., Walker, J. W. T., Smylie, M., & Sawyer, M. B. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.03.001 · Cited by 13
Self-citationRelationships among microbiota, gastric cancer, and immunotherapy
Li, Y., Huang, X., Tong, D., Jiang, C., Zhu, X., Wei, Z., Gong, T., & Jin, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.987763 · Cited by 15
“Blocking immune checkpoints, such as cytotoxic T lymphocyte associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD1), and its ligands (PD-L1 or B7-H1), have proved effective for several solid cancers (Ansell et al., 2015; Motzer et al., 2015; Ferris et al., 2016; Antonia et al., 2017; Weber et al., 2017).”
BackgroundCastle, J. T., Adatorwovor, R., Levy, B. E., Marcinkowski, E., Merritt, A. S., Stapleton, J. L., & Burke, E. E. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12745-0 · Cited by 13
Vuillamy, C., Arnault, J., Fuméry, M., Mortier, L., Monestier, S., Mansard, S., Bens, G., Duval-Modeste, A.-B., Funck‐Brentano, E., Jeudy, G., et al. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000878 · Cited by 13
Self-citationPlaczke, J., Rosińska, M., Sobczuk, P., Ziętek, M., Kempa-Kamińska, N., Cybulska-Stopa, B., Kamińska‐Winciorek, G., Bal, W., Mackiewicz, J., Galus, Ł., et al. (2023) · Cancers · doi:10.3390/cancers15174384 · Cited by 14
Self-citationBührer, E., Kiciński, M., Mandalà, M., Pe, M. L., Long, G. V., Atkinson, V. G., Blank, C. U., Haydon, A. M., Dalle, S., Khattak, A., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00338-3 · Cited by 16
Self-citationStadler, R., Leiter, U., & Garbe, C. (2018) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13707 · Cited by 13
Prinzen, T., Klein, M., Hallermann, C., & Wermker, K. (2019) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2019.06.012 · Cited by 13
An overview of binimetinib for the treatment of melanoma
Specenier, P. M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1729122 · Cited by 13
Current management of melanoma patients with nodal metastases
Han, D., van Akkooi, A. C. J., Straker, R. J., Shannon, A. B., Karakousis, G. C., Wang, L., Kim, K. B., & Reintgen, D. S. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10099-7 · Cited by 14
Hieken, T. J., Price, D. L., Piltin, M. A., Turner, H. J., & Block, M. S. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11112-9 · Cited by 13
“Three-year recurrence-free survival for patients with IIIB/C disease in the treatment arm of these adjuvant trials remains * 50% and 15–20% of patients screened for these adjuvant trials were ineligible due to progression after operation.(6,7) This has led to great current interest in exploring neoadjuvant systemic th…”
MethodFox, J. A., Langbecker, D., Rosenberg, J. P., & Ekberg, S. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17511 · Cited by 13
Current controversies in early-stage melanoma
Klapperich, M. E., Bowen, G. M., & Grossman, D. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.054 · Cited by 13
Nebenwirkungen neuer onkologischer Immuntherapien
Braun, G. S., Kirschner, M., Rübben, A., Wahl, R. U., Amann, K., Benesova, K., & Leipe, J. (2020) · Der Nephrologe · doi:10.1007/s11560-020-00424-8 · Cited by 19
Sobrero, A. F., Pastorino, A., & Zalcberg, J. R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01531 · Cited by 13
Gjorup, C. A., Woodford, R. G., Li, I., Carlino, M. S., Ch’ng, S., Chung, D. K. V., Hsiao, E., Lo, S., London, K., Long, G. V., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14526-9 · Cited by 12
Self-citationTissue biomarkers of immune checkpoint inhibitor therapy
Davoudi, F., Moradi, A., Sadeghirad, H., & Kulasinghe, A. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12723 · Cited by 15
“26 Furthermore, a current IMMUNED phase II randomized trial showcased the combined impact of nivolumab and ipilimumab, revealing a greater 2-year recurrence-free survival rate (70% vs .”
BackgroundKhan, B., Qahwaji, R. M., Alfaifi, M. S., & Mobashir, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060732 · Cited by 20
“However, a thorough understanding is required for the best possible clinical management due to the wide range of immune-related side effects linked to these medicines, which affect several organ systems, including the central nervous system and ocular symptoms [5,6,17–19].”
BackgroundPrognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
Valdez, C. N., Sánchez‐Zuno, G. A., Osmani, L., Ibrahim, W., Galan, A., Bacchiocchi, A., Halaban, R., Kulkarni, R. P., Kang, I., Bucala, R., et al. (2024) · Oncotarget · doi:10.18632/oncotarget.28615 · Cited by 13
Salem, A. F., Chen, M., Williams, M. D., Swanson, D. M., McQuade, J. L., Amaria, R. N., Hanna, E. Y., Bishop, A. J., Farooqi, A. S., Guadagnolo, B. A., et al. (2025) · Head & Neck · doi:10.1002/hed.28098 · Cited by 16
“KEYNOTE-054 and CheckMate 238 demonstrated the benefits of adjuvant single-agent anti-PD1, but notably, KEYNOTE-054 excluded mucosal melanoma patients while such patients made up only 3% of those enrolled on CheckMate 238 [27, 28].”
Lodde, G. C., Hassel, J. C., von Wasielewski, I., Meier, F. E., Mohr, P., Kähler, K. C., Hauschild, A., Glutsch, V., Stege, H. M., Berking, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02776 · Cited by 12
Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma
Eroglu, Z., & Özgün, A. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1512402 · Cited by 14
“83)[28], both BRAF/MEK-inhibitor and anti-PD-1 therapy have become feasible adjuvant options for these patients.”
BackgroundMohr, P., Kiecker, F., Soriano, V., Dereure, O., Mujika, K., Saïag, P., Utikal, J. S., Koneru, R., Robert, C., Cuadros, F., et al. (2019) · Melanoma Management · doi:10.2217/mmt-2019-0015 · Cited by 12
Master protocols in immuno-oncology: do novel drugs deserve novel designs?
Mazzarella, L., Morganti, S., Marra, A., Trapani, D., Tini, G., Pelicci, P. G., & Curigliano, G. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000475 · Cited by 14
“Also, the increasing adoption of IO in the early settings 64–66 creates a growing cohort of patients with a history of treatment with ICI.”
The Role of Neoadjuvant Therapy in Melanoma
Kelly, Z. R., Gorantla, V. C., & Davar, D. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00944-5 · Cited by 13
Song, X., Lu, Z., & Xu, J. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9054 · Cited by 12
“Anti-cytotoxic T-lymphocyte associated protein 4 (anti-CTLA4), an example of an immune checkpoint blockades, displayed promising anti-tumor effects in various cancers, including melanoma and colon and lung cancer (11-13); however, to the best of our knowledge, their effect has not been investigated in PDAC to date (14…”
BackgroundNodular primary cutaneous melanoma is associated with PD-L1 expression
Bianchi, M. G., Junior, P. F. G.-B., Sotto, M. N., Rodig, S. J., Mihm, M. C., Neto, C. F., Duncan, L. M., & Kalil, J. E. (2020) · European Journal of Dermatology · doi:10.1684/ejd.2020.3846 · Cited by 12
Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse
Jansen, Y. J. L., Willekens, I., Seremet, T., Awada, G., Schwarze, J. K., Mey, J. D., Brussaard, C. C., & Neyns, B. (2021) · Cancers · doi:10.3390/cancers13030442 · Cited by 12
“Current adjuvant therapy with anti-PD-1 antibodies or targeted therapy in BRAF V600 mutant melanoma has improved 3-year RFS in high-risk stage III melanoma to 43–58% [3,4].”
BackgroundThe ROC of Cox proportional hazards cure models with application in cancer studies
Zhang, Y., Han, X., & Shao, Y. (2021) · Lifetime Data Analysis · doi:10.1007/s10985-021-09516-6 · Cited by 15
Indini, A., Roila, F., Grossi, F., Massi, D., & Mandalà, M. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00608-5 · Cited by 13
“In both trials, the survival improvement of adjuvant anti-PD1 was consistent across all patient subgroups, regardless of disease stage and BRAF mutational status [13, 15].”
BackgroundMethod
Metadata
- Authors
- Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J.-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., & Ascierto, P. A.
- Affiliations
- University of Siena (IT)
- ORCID
- Weber, Jeffrey
- Gogas, Helen J.
- Arance, Ana M.
- Cowey, C. Lance
- Dalle, Stéphane
- Schenker, Michael
- Grob, Jean-Jacques
- Butler, Marcus O.
- Middleton, Mark R.
- Maio, Michele
- Atkinson, Victoria
- Queirolo, Paola
- Gonzalez, Rene
- Kudchadkar, Ragini R.
- Smylie, Michael
- Mortier, Laurent
- Atkins, Michael B.
- Long, Georgina V.
- Bhatia, Shailender
- Rutkowski, Piotr
- Yokota, Kenji
- Yamazaki, Naoya
- Sabater, Javier
- Larkin, James
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-09
- Volume
- 377
- Issue
- 19
- Pages
- 1824-1835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752227448
- Cited by
- 2,246
- References
- 19
- Citations by year
- 2026: 105 · 2025: 155 · 2024: 218 · 2023: 228 · 2022: 265 · 2021: 339 · 2020: 347 · 2019: 315 · 2018: 245 · 2017: 24
- FWCI
- 112.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Cancer Research UK (18892, 15951, 20613, 22795)
- Medical Research Council (MR/P024351/1)
- Japan Society for the Promotion of Science (16K10165)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, adjuvant therapy, advanced melanoma, immune checkpoint inhibitors, recurrence-free survival, PD-1 inhibitors, CTLA-4 inhibitors, R0 resection, treatment-related adverse events, melanoma recurrence, overall survival, progression-free survival
- MeSH terms
- Ipilimumab, Nivolumab, Cutaneous Malignant Melanoma, Adjuvants, Immunologic, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.